MX2023001187A - Composiciones y métodos para una vacunación mejorada. - Google Patents

Composiciones y métodos para una vacunación mejorada.

Info

Publication number
MX2023001187A
MX2023001187A MX2023001187A MX2023001187A MX2023001187A MX 2023001187 A MX2023001187 A MX 2023001187A MX 2023001187 A MX2023001187 A MX 2023001187A MX 2023001187 A MX2023001187 A MX 2023001187A MX 2023001187 A MX2023001187 A MX 2023001187A
Authority
MX
Mexico
Prior art keywords
orf
compositions
ops
mirna
methods
Prior art date
Application number
MX2023001187A
Other languages
English (en)
Inventor
Valerie Duval
Romain Micol
Original Assignee
Combined Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/019028 external-priority patent/WO2021168405A1/en
Application filed by Combined Therapeutics Inc filed Critical Combined Therapeutics Inc
Publication of MX2023001187A publication Critical patent/MX2023001187A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una composición que comprende un primer constructo de mARN que comprende un primer marco de lectura abierto (ORF), en donde el primer ORF codifica un antígeno; en donde el primer ORF está ligado operativamente a al menos una región no traducida (UTR), en donde la UTR comprende al menos una primera secuencia de protección de órganos (OPS), y en donde la primera OPS comprende al menos dos secuencias diana de micro-ARN (miARN), en donde cada una de las al menos dos secuencias diana de miARN está optimizada para hibridarse con una secuencia de miARN correspondiente; además, se proporcionan composiciones adicionales que comprenden constructos de mARN que comprenden un ORF y una OPS en donde la ORF codifica una citocina proinflamatoria, y métodos que incluyen una o ambas de estas composiciones para el tratamiento y a la prevención de enfermedades tal como la enfermedad patógena.
MX2023001187A 2020-07-31 2021-07-30 Composiciones y métodos para una vacunación mejorada. MX2023001187A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059458P 2020-07-31 2020-07-31
PCT/US2021/019028 WO2021168405A1 (en) 2020-02-21 2021-02-22 Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
PCT/US2021/043975 WO2022035621A1 (en) 2020-07-31 2021-07-30 Compositions and methods for improved vaccination

Publications (1)

Publication Number Publication Date
MX2023001187A true MX2023001187A (es) 2023-04-04

Family

ID=80248099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001187A MX2023001187A (es) 2020-07-31 2021-07-30 Composiciones y métodos para una vacunación mejorada.

Country Status (11)

Country Link
US (1) US20240024451A1 (es)
EP (1) EP4188393A1 (es)
JP (1) JP2023536844A (es)
KR (1) KR20230083266A (es)
CN (1) CN116209771A (es)
AU (1) AU2021326420A1 (es)
BR (1) BR112023001563A2 (es)
CA (1) CA3187345A1 (es)
IL (1) IL300247A (es)
MX (1) MX2023001187A (es)
WO (1) WO2022035621A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117821482A (zh) * 2024-03-05 2024-04-05 中国人民解放军军事科学院军事医学研究院 一种编码猴痘病毒和新冠病毒单组份融合抗原的mRNA疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
AU2015289573A1 (en) 2014-07-17 2017-02-02 Modernatx, Inc Terminal modifications of polynucleotides
MX2018009126A (es) 2016-01-27 2019-08-21 Oncorus Inc Vectores virales oncoliticos y usos de estos.
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
CN111954535A (zh) 2018-02-19 2020-11-17 联合治疗公司 用于编码核糖核酸的器官保护性表达和调节的组合物和方法

Also Published As

Publication number Publication date
AU2021326420A1 (en) 2023-03-09
KR20230083266A (ko) 2023-06-09
EP4188393A1 (en) 2023-06-07
BR112023001563A2 (pt) 2023-10-10
JP2023536844A (ja) 2023-08-30
CA3187345A1 (en) 2022-02-17
CN116209771A (zh) 2023-06-02
WO2022035621A1 (en) 2022-02-17
US20240024451A1 (en) 2024-01-25
IL300247A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
MX2020011805A (es) Agentes de iarn para infeccion causada por el virus de la hepatitis b.
WO2021155243A8 (en) Respiratory virus immunizing compositions
NZ586238A (en) Methods and compositions for immunizing pigs against porcine circovirus
ZA202208795B (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
AR048596A1 (es) Atenuacion sinergica del virus de estomatitis vesiculosa, sus vectores y sus composiciones inmunogenas
Liu et al. Identification and analysis of a Sciaenops ocellatus ISG15 homologue that is involved in host immune defense against bacterial infection
US10653769B2 (en) iDNA vaccines and methods for using the same
MX2020003100A (es) Composiciones y metodos para la liofilizacion de bacterias o cepas de listeria.
MX2023001187A (es) Composiciones y métodos para una vacunación mejorada.
CO6511253A2 (es) Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma
MX2022015169A (es) Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos.
WO2020123508A3 (en) Rnai constructs for inhibiting pnpla3 expression
GB2458057A (en) Francisella strain for live vaccine
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
Porntrakulpipat et al. RNA interference targeting nucleocapsid protein (C) inhibits classical swine fever virus replication in SK-6 cells
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
AR103920A1 (es) Moléculas de ácido nucleico de ii215 de arn polimerasa para el control de plagas de insectos
MX2023001786A (es) Construcciones de iarn y metodos para inhibir la expresion de marc1.
EP4233912A3 (en) Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
KR101677231B1 (ko) 무혈청배지（serum free medium）를 이용한 메갈로사이티바이러스의 효율적 제조방법
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
MX2022001742A (es) Metodos para prevenir el dengue y la hepatitis a.
IŞININA Detection of apoptosis feature in ultraviolet light-exposed Trichophyton rubrum
Kumar et al. siRNAs encapsulated in recombinant capsid protein derived from Dengue serotype 2 virus inhibits the four serotypes of the virus and proliferation of cancer cells